ATMA will use Filament’s proprietary botanical drug candidate for clinical trials VANCOUVER, BC, Feb. 23, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with ATMA Journey Centers (“ATMA”). ATMA is Canada’s first private…
